Related Experiment Video

Updated: Nov 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis

Robert J Fox1, Richard J Kryscio2

  • 1From the Mellen Center for Multiple Sclerosis Treatment and Research (R.J.F.), Neurological Institute, Cleveland Clinic, OH; and Department of Statistics and Sanders Brown Center on Aging (R.J.K.), University of Kentucky, Lexington. foxr@ccf.org.

Neurology
|May 26, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.5K

Related Experiment Videos

Last Updated: Nov 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

Clinicians' and patients' perspectives of a mobility technician role in the hospital to promote ambulation: A qualitative study.

Journal of hospital medicine·2026

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.

Multiple sclerosis journal - experimental, translational and clinical·2026

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.

Expert opinion on investigational drugs·2026

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.

Drugs·2026

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Neurology·2026

Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.

Neurology·2026

The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.

Neurology·2026

Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial.

Neurology·2026

Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.

Neurology·2026

Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.

Neurology·2026

Comparative Risk of Respiratory Virus Infections Among Patients with Asthma Treated with Biologic Therapies.

QJM : monthly journal of the Association of Physicians·2026

Biomarker-Guided Management in Vitreoretinal Diseases: Integrating Imaging, Pharmacotherapy, and Surgical Decision-Making-A Narrative Review.

Retina (Philadelphia, Pa.)·2026

Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.

Antiviral therapy·2026

Industry updates in advanced therapy medicinal products and regenerative medicine - July 2026.

Regenerative medicine·2026

In Regulatory First, Myeloma Drug Approved Based on MRD Negativity.

Cancer discovery·2026

Structure and allostery in major facilitator superfamily symport mechanisms.

Acta crystallographica. Section D, Structural biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us